Minimally Invasive Glaucoma Surgery (MIGS) Devices Market Report 2026
Minimally Invasive Glaucoma Surgery (MIGS) Devices Market Report 2026
Global Outlook – By Product Type (Trabecular Micro-Stents, Subconjunctival Micro-Shunts, Suprachoroidal Stents, Canaloplasty & Schlemm’s Canal Devices), By Surgical Approach (MIGS in Conjunction with Cataract Surgery, Stand-Alone MIGS Procedures), By Target Anatomical Pathway (Trabecular Meshwork, Schlemm’s Canal, Suprachoroidal Space, Subconjunctival Space), By Procedure Type (Ab-Interno MIGS, Ab-Externo MIGS), By End User (Ophthalmology Clinics, Ambulatory Surgery Centers (ASCs), Specialized Eye Hospitals) – Market Size, Trends, Strategies, and Forecast to 2035
Minimally Invasive Glaucoma Surgery (MIGS) Devices Market Overview
• Minimally Invasive Glaucoma Surgery (MIGS) Devices market size has reached to $0.89 billion in 2025 • Expected to grow to $2.79 billion in 2030 at a compound annual growth rate (CAGR) of 24.9% • Growth Driver: Rising Prevalence of Glaucoma Spurs Demand for Minimally Invasive Glaucoma Surgery (MIGS) Devices • Market Trend: Commercial Launch Of Sustained Release Intraocular Implant For Improved Glaucoma Treatment Outcomes • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.
What Is Covered Under Minimally Invasive Glaucoma Surgery (MIGS) Devices Market?
Minimally invasive glaucoma surgery (MIGS) devices are medical instruments designed to lower intraocular pressure (IOP) in patients with glaucoma through less invasive surgical techniques compared to traditional glaucoma surgeries. These devices aim to reduce the risk of complications, shorten recovery time, and improve patient outcomes by offering a safer and less invasive option for patients needing surgical intervention to manage their condition. The main product types of minimally invasive glaucoma surgery (MIGS) devices are valves, glaucoma drainage implants, glaucoma tube shunts, stents, and others. A glaucoma drainage implant, also known as an aqueous shunt or tube shunt, is a small medical device surgically placed in the eye to treat glaucoma. These are used for various surgeries such as glaucoma in conjunction with cataracts, stand stand-alone glaucoma with various targets that include trabecular meshwork, suprachoroidal space, and others. These are distributed through various distribution channels such as direct tender, and retail sales and also by various end users such as ophthalmology clinics, ambulatory surgery centers (ASCS), and others.
What Is The Minimally Invasive Glaucoma Surgery (MIGS) Devices Market Size and Share 2026?
The minimally invasive glaucoma surgery (migs) devices market size has grown exponentially in recent years. It will grow from $0.89 billion in 2025 to $1.14 billion in 2026 at a compound annual growth rate (CAGR) of 28.1%. The growth in the historic period can be attributed to increasing prevalence of glaucoma, growing aging population, limitations of conventional glaucoma surgeries, rising awareness of vision preservation, increasing adoption of cataract surgeries.What Is The Minimally Invasive Glaucoma Surgery (MIGS) Devices Market Growth Forecast?
The minimally invasive glaucoma surgery (migs) devices market size is expected to see exponential growth in the next few years. It will grow to $2.79 billion in 2030 at a compound annual growth rate (CAGR) of 24.9%. The growth in the forecast period can be attributed to expanding glaucoma patient pool, growing acceptance of minimally invasive surgical options, rising demand for outpatient ophthalmic procedures, increasing focus on quality-of-life outcomes, expanding access to specialized ophthalmology clinics. Major trends in the forecast period include rising adoption of minimally invasive glaucoma procedures, growing preference for MIGS in early and moderate glaucoma, increasing use of MIGS in combination with cataract surgery, expansion of outpatient and ambulatory glaucoma surgeries, growing demand for safer and faster-recovery glaucoma treatments.Global Minimally Invasive Glaucoma Surgery (MIGS) Devices Market Segmentation
1) By Product Type: Trabecular Micro-Stents, Subconjunctival Micro-Shunts, Suprachoroidal Stents, Canaloplasty & Schlemm’s Canal Devices 2) By Surgical Approach: MIGS in Conjunction with Cataract Surgery, Stand-Alone MIGS Procedures 3) By Target Anatomical Pathway: Trabecular Meshwork, Schlemm’s Canal, Suprachoroidal Space, Subconjunctival Space 4) By Procedure Type: Ab-Interno MIGS, Ab-Externo MIGS 5) By End User: Ophthalmology Clinics, Ambulatory Surgery Centers (ASCs), Specialized Eye Hospitals Subsegments: 1) By Trabecular Micro-Stents: Single-Lumen Trabecular Micro-Stents, Multi-Lumen Trabecular Micro-Stents, Scaffold-Based Trabecular Stents, Drug-Eluting Trabecular Micro-Stents 2) By Subconjunctival Micro-Shunts: Gel-Based Micro-Shunts, Polymer-Based Micro-Shunts, Collagen-Based Micro-Shunts, Fixed-Lumen Subconjunctival Micro-Shunts 3) By Suprachoroidal Stents: Passive Suprachoroidal Stents, Flow-Regulated Suprachoroidal Stents, Biocompatible Polymer Suprachoroidal Stents 4) By Canaloplasty & Schlemm’s Canal Devices: Microcatheter-Based Canaloplasty Devices, Viscodilation & Schlemm’s Canal Expanders, Implant-Free Canaloplasty Systems, Schlemm’s Canal Scaffolding DevicesWhat Is The Driver Of The Minimally Invasive Glaucoma Surgery (MIGS) Devices Market?
The increasing prevalence of eye disorders is expected to propel the growth of minimally invasive glaucoma surgery (MIGS) devices going forward. Eye disorders encompass a wide range of conditions that affect the eyes and vision. The prevalence of eye disorders is increasing due to lifestyle changes, environmental influences, and aging populations. Minimally invasive glaucoma surgery (MIGS) devices are innovative tools utilized in managing various eye diseases, primarily focusing on reducing intraocular pressure (IOP) to prevent or control glaucoma progression. For instance, in 2024, according to the National Eye Institute, a US-based government agency, around 2.2 million Americans will be blind or partially blind by 2030. Therefore, the increasing prevalence of eye disorders drives the minimally invasive glaucoma surgery (MIGS) devices industry.Key Players In The Global Minimally Invasive Glaucoma Surgery (MIGS) Devices Market
Major companies operating in the minimally invasive glaucoma surgery (migs) devices market are Glaukos Corporation, Sight Sciences Inc., Alcon Inc., Johnson & Johnson Vision Care Inc., Bausch & Lomb Incorporated, Carl Zeiss Meditec AG, Nova Eye Medical Limited, iSTAR Medical SA, New World Medical Inc., MicroSurgical Technology Inc., ASICO LLC, Ziemer Ophthalmic Systems AG, Ellex Medical Lasers Ltd., Lumenis Ltd., Iridex Corporation, Katena Products Inc., Oertli Instrumente AG, Sifi S.p.A., Aquesys Inc., Beaver‑Visitec InternationalGlobal Minimally Invasive Glaucoma Surgery (MIGS) Devices Market Trends and Insights
Major companies operating in the minimally invasive glaucoma surgery (MIGS) devices market are focusing on developing advanced solutions, such as sustained-release drug-delivery implants, to replace traditional topical glaucoma treatments. A sustained-release implant refers to a device that delivers medication continuously over time, improving patient adherence, reducing dosing frequency, and enhancing treatment efficacy. For instance, in February 2024, Celanese Corporation, a US-based specialty materials company, partnered with Glaukos to commercially launch the iDose® TR (Travoprost Intracameral Implant) using Celanese’s VitalDose® Ethylene Vinyl Acetate (EVA) platform. This innovation replaces traditional eye-drop regimens by providing continuous intraocular delivery of travoprost directly to the eye over several months. Integrated with Glaukos’ MIGS portfolio, it offers a minimally invasive therapeutic option that reduces the need for daily eye drops, improves patient compliance, and supports sustained intraocular pressure control, ultimately enhancing long-term treatment outcomes.What Are Latest Mergers And Acquisitions In The Minimally Invasive Glaucoma Surgery (MIGS) Devices Market?
In July 2024, Alcon Inc, a Switzerland-based medical device company, acquired BELKIN Vision Inc. for $81 million. With this acquisition, Alcon aims to accelerate the global adoption of Direct Selective Laser Trabeculoplasty (DSLT) as a first-line treatment for glaucoma. BELKIN Vision Inc. is an Israel-based medical device company that specializes in the development and manufacturing of glaucoma laser therapy devices.Regional Outlook
North America was the largest region in the minimally invasive glaucoma surgery (MIGS) devices market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, SpainWhat Defines the Minimally Invasive Glaucoma Surgery (MIGS) Devices Market?
The minimally invasive glaucoma surgery (MIGS) devices market consists of revenues earned by entities by providing canal-based procedures, viscocanalostomy, and canaloplasty procedures. The market value includes the value of related goods sold by the service provider or included within the service offering. The minimally invasive glaucoma surgery (MIGS) devices market also includes sales of glaucoma drainage implants, glaucoma tube shunts, and invasive devices. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.How is Market Value Defined and Measured?
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.Minimally Invasive Glaucoma Surgery (MIGS) Devices Market Report Forecast Analysis
| Report Attribute | Details |
|---|---|
| Market Size Value In 2026 | $1.14 billion |
| Revenue Forecast In 2035 | $2.79 billion |
| Growth Rate | CAGR of 28.1% from 2026 to 2035 |
| Base Year For Estimation | 2025 |
| Actual Estimates/Historical Data | 2020-2025 |
| Forecast Period | 2026 - 2030 - 2035 |
| Market Representation | Revenue in USD Billion and CAGR from 2026 to 2035 |
| Segments Covered | Product Type, Surgical Approach, Target Anatomical Pathway, Procedure Type, End User |
| Regional Scope | Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa |
| Country Scope | The countries covered in the report are Australia, Brazil, China, France, Germany, India, ... |
| Key Companies Profiled | Glaukos Corporation, Sight Sciences Inc., Alcon Inc., Johnson & Johnson Vision Care Inc., Bausch & Lomb Incorporated, Carl Zeiss Meditec AG, Nova Eye Medical Limited, iSTAR Medical SA, New World Medical Inc., MicroSurgical Technology Inc., ASICO LLC, Ziemer Ophthalmic Systems AG, Ellex Medical Lasers Ltd., Lumenis Ltd., Iridex Corporation, Katena Products Inc., Oertli Instrumente AG, Sifi S.p.A., Aquesys Inc., Beaver‑Visitec International |
| Customization Scope | Request for Customization |
| Pricing And Purchase Options | Explore Purchase Options |
Frequently Asked Questions
The Minimally Invasive Glaucoma Surgery (MIGS) Devices Market Report 2026 market was valued at $0.89 billion in 2025, increased to $1.14 billion in 2026, and is projected to reach $2.79 billion by 2030.
The expected CAGR for the Minimally Invasive Glaucoma Surgery (MIGS) Devices Market Report 2026 market during the forecast period 2025–2030 is 24.9%.
Major growth driver of the market includes: Rising Prevalence of Glaucoma Spurs Demand for Minimally Invasive Glaucoma Surgery (MIGS) Devices in the Minimally Invasive Glaucoma Surgery (MIGS) Devices Market Report 2026 market. For further insights on this market,
The minimally invasive glaucoma surgery (migs) devices market covered in this report is segmented –
1) By Product Type: Trabecular Micro-Stents, Subconjunctival Micro-Shunts, Suprachoroidal Stents, Canaloplasty & Schlemm’s Canal Devices
2) By Surgical Approach: MIGS in Conjunction with Cataract Surgery, Stand-Alone MIGS Procedures
3) By Target Anatomical Pathway: Trabecular Meshwork, Schlemm’s Canal, Suprachoroidal Space, Subconjunctival Space
4) By Procedure Type: Ab-Interno MIGS, Ab-Externo MIGS
5) By End User: Ophthalmology Clinics, Ambulatory Surgery Centers (ASCs), Specialized Eye Hospitals Subsegments:
1) By Trabecular Micro-Stents: Single-Lumen Trabecular Micro-Stents, Multi-Lumen Trabecular Micro-Stents, Scaffold-Based Trabecular Stents, Drug-Eluting Trabecular Micro-Stents
2) By Subconjunctival Micro-Shunts: Gel-Based Micro-Shunts, Polymer-Based Micro-Shunts, Collagen-Based Micro-Shunts, Fixed-Lumen Subconjunctival Micro-Shunts
3) By Suprachoroidal Stents: Passive Suprachoroidal Stents, Flow-Regulated Suprachoroidal Stents, Biocompatible Polymer Suprachoroidal Stents
4) By Canaloplasty & Schlemm’s Canal Devices: Microcatheter-Based Canaloplasty Devices, Viscodilation & Schlemm’s Canal Expanders, Implant-Free Canaloplasty Systems, Schlemm’s Canal Scaffolding Devices
1) By Product Type: Trabecular Micro-Stents, Subconjunctival Micro-Shunts, Suprachoroidal Stents, Canaloplasty & Schlemm’s Canal Devices
2) By Surgical Approach: MIGS in Conjunction with Cataract Surgery, Stand-Alone MIGS Procedures
3) By Target Anatomical Pathway: Trabecular Meshwork, Schlemm’s Canal, Suprachoroidal Space, Subconjunctival Space
4) By Procedure Type: Ab-Interno MIGS, Ab-Externo MIGS
5) By End User: Ophthalmology Clinics, Ambulatory Surgery Centers (ASCs), Specialized Eye Hospitals Subsegments:
1) By Trabecular Micro-Stents: Single-Lumen Trabecular Micro-Stents, Multi-Lumen Trabecular Micro-Stents, Scaffold-Based Trabecular Stents, Drug-Eluting Trabecular Micro-Stents
2) By Subconjunctival Micro-Shunts: Gel-Based Micro-Shunts, Polymer-Based Micro-Shunts, Collagen-Based Micro-Shunts, Fixed-Lumen Subconjunctival Micro-Shunts
3) By Suprachoroidal Stents: Passive Suprachoroidal Stents, Flow-Regulated Suprachoroidal Stents, Biocompatible Polymer Suprachoroidal Stents
4) By Canaloplasty & Schlemm’s Canal Devices: Microcatheter-Based Canaloplasty Devices, Viscodilation & Schlemm’s Canal Expanders, Implant-Free Canaloplasty Systems, Schlemm’s Canal Scaffolding Devices
Major trend in this market includes: Commercial Launch Of Sustained Release Intraocular Implant For Improved Glaucoma Treatment Outcomes For further insights on this market,
Request for SampleMajor companies operating in the Minimally Invasive Glaucoma Surgery (MIGS) Devices Market Report 2026 market are Major companies operating in the minimally invasive glaucoma surgery (migs) devices market are Glaukos Corporation, Sight Sciences Inc., Alcon Inc., Johnson & Johnson Vision Care Inc., Bausch & Lomb Incorporated, Carl Zeiss Meditec AG, Nova Eye Medical Limited, iSTAR Medical SA, New World Medical Inc., MicroSurgical Technology Inc., ASICO LLC, Ziemer Ophthalmic Systems AG, Ellex Medical Lasers Ltd., Lumenis Ltd., Iridex Corporation, Katena Products Inc., Oertli Instrumente AG, Sifi S.p.A., Aquesys Inc., Beaver‑Visitec International
North America was the largest region in the minimally invasive glaucoma surgery (MIGS) devices market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the minimally invasive glaucoma surgery (migs) devices market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.